Prevalence of human leukocyte antigen-B*5701 among HIV-infected children in Thailand and Cambodia: Implications for abacavir use

Pediatric Infectious Disease Journal

Volumn 32, Issue 3, 2013, Pages 252-253

  Puthanakit, Thanyawee ^a   Bunupuradah, Torsak ^a   Kosalaraksa, Pope ^b   Vibol, Ung ^c   Hansudewechakul, Rawiwan ^d   Ubolyam, Sasiwimol ^a   Suwanlerk, Tulathip ^a   Kanjanavanit, Suparat ^e   Ngampiyaskul, Chaiwat ^f   Wongsawat, Jurai ^g   Luesomboon, Wicharn ^h   Vonthanak, Saphonn ⁱ   Ananworanich, Jintanat ^a   Ruxrungtham, Kiat ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c National Pediatric Hospital   (Cambodia)

^d CHIANGRAI PRACHANUKROH HOSPITAL   (Thailand)

^e NAKORNPING HOSPITAL   (Thailand)

^f PRAPOKKLAO HOSPITAL   (Thailand)

^g Bamrasnaradura Infectious Disease Institute   (Thailand)

^h Queen Savang Vadhana Memorial Hospital   (Thailand)

ⁱ National Center for HIV/AIDS   (Cambodia)

Author keywords

Abacavir hypersensitivity; HIV; Human leukocyte antigen B*5701

Indexed keywords

ABACAVIR; HLA B ANTIGEN; HLA B5701 ANTIGEN; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; CAMBODIA; CHILD; CHILDHOOD DISEASE; COUGHING; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GENE FREQUENCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY TRACT DISEASE; SORE THROAT; THAILAND;

CAMBODIA; CHILD; CHILD, PRESCHOOL; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; INFANT; MALE; PREVALENCE; THAILAND;

EID: 84876294238     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182745dba     Document Type: Article

References (15)

1. Green H, Gibb DM, Walker AS, et al.; Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virologi-cal superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947-955.
2. Welch S, Sharland M, Lyall EG, et al.; PENTA Steering Committee. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med. 2009;10:591-613.
3. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603-1614.
4. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005;19:979-981.
5. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. lancet. 2002;359: 1121-1122.
6. *5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358: 568-579.
7. *5701 in HIV-1-infected UK subjects. HIV Med. 2010;11:187-192.
8. *5701 screenmg be performed in every ethnic group before starting abacavir? Clin Infect Dis. 2009;48:365-367.
9. *5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother. 2007;60:599-604.
10. Puthanakit T, Vonthanak S, Ananworanich J, et al.; on behalf of the PREDICT Study Group. Early versus deferred antiretroviral therapy for HIV-infected children older than one year of age: PREDICT - a randomised study. Lancet Infect Dis 2012 Oct 8 [Epub ahead of print].
11. Saito S, Ota S, Yamada E, et al. Allele frequencies and haplotypic associations denned by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens. 2000;56:522-529.
12. Pimtanothai N, Charoenwongse P, Mutirangura A, et al. Distribution of HLA-B alleles in nasopharyngeal carcinoma patients and normal controls in Thailand. Tissue Antigens. 2002;59:223-225.
13. Kauf TL, Farkouh RA, Earnshaw SR, et al. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV Pharmacoeconomics. 2010;28:1025-1039.
14. *5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany. Eur J Med Res. 2010;15:145-151.
15. *57:01 detection by real-time PCR. Pharmacogenomics. 2011;12:567-576.